NCT07327294
尚未招募
1 期
An Open-label, Multicenter Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of XNW34017 in Patients With Advanced Solid Tumors
Evopoint Biosciences Inc.1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2026年1月31日最近更新:
干预措施XNW34017
概览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- Evopoint Biosciences Inc.
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- The incidence and severity of AEs and SAEs
概览
简要总结
This study is an open-label, dose-escalation, multicenter Phase I/II study conducted in patients with advanced solid tumors. The target population for this study consists of patients with advanced solid tumors who have failed or are intolerant to standard treatments. The study is divided into two parts: the dose-escalation phase and the dose-expansion phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Dose escalation phase: Subjects with advanced and/or metastatic malignant solid tumors who have failed standard treatment or lack effective standard treatment, and have histologically or cytologically confirmed diagnosis.
- •Dose expansion phase, including but not limited to: Advanced and/or metastatic small cell lung cancer, prostate cancer, etc., with disease progression confirmed by histopathology, and failure in the following anti-cancer treatments:
- •Small cell lung cancer: Patients with small cell lung cancer who have progressed or relapsed after receiving at least two prior systemic treatment regimens.
- •Metastatic castration-resistant prostate cancer (mCRPC): Patients who have previously received treatment with enzalutamide or abiraterone and have experienced disease progression. At screening, serum testosterone should be at castration levels (≤ 50 ng/dL or ≤ 1.73 nmol/L). For patients who have not undergone bilateral orchiectomy, LHRHa therapy should be administered ≥ 4 weeks prior to the first dose of study treatment and continued throughout the study.
- •The subject must be ≥ 18 years of age at the time of signing the informed consent.
- •At least one measurable lesion according to RECIST 1.1 criteria (applicable to the backfill cohort and dose expansion phase).
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 -
- •The subject's organ function levels must meet the following requirements within 7 days prior to the first dose:
- •Absolute Neutrophil Count (ANC) ≥ 1.5×10\^9/L, Platelet Count ≥ 100×10\^9/L, Hemoglobin ≥ 90 g/L; Creatinine Clearance ≥ 60 ml/min (calculated using the Cockcroft-Gault formula) or Serum Creatinine (Cr) ≤ 1.5 times the upper limit of normal; Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) levels ≤ 2.5 times the upper limit of normal (ULN), for liver cancer/liver metastasis patients, AST/ALT should be ≤ 5×ULN; Total Bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN), for patients with Gilbert's Syndrome, Direct Bilirubin (DBIL) must be ≤ 2×ULN; International Normalized Ratio (INR) ≤ 1.2 (without anticoagulant treatment), Activated Partial Thromboplastin Time (APTT) ≤ 1.25×ULN; for subjects who have been on stable-dose anticoagulant therapy (e.g., warfarin) for ≥8 weeks, INR must be ≤
- •Life expectancy ≥ 12 weeks.
排除标准
- •Individuals who have had an allergic reaction to any component of the XNW
- •The washout period of prior antitumor treatments before the first study drug treatment is insufficient, defined as follows:
- •Chemotherapy, small molecule targeted therapy, or endocrine therapy \< 2 weeks or 5 half-lives, whichever is shorter; Monoclonal antibody therapy \< 3 weeks; Brain radiotherapy \< 2 weeks, palliative radiotherapy \< 2 weeks, curative radiotherapy \< 4 weeks.
- •Subjects with double primary malignant tumors, except for the specific cancer being studied in this trial and any previously cured local tumors: non-invasive basal cell carcinoma or squamous cell carcinoma, non-invasive superficial bladder cancer, and any other tumors with a complete remission (CR) lasting more than 5 years.
- •Receiving a live vaccine within 4 weeks prior to the first study drug treatment. Note: Seasonal flu vaccines are generally inactivated vaccines and can be used; however, intranasal flu vaccines, which are live attenuated vaccines, are not permitted.
- •Use of granulocyte colony-stimulating factor (G-CSF) or granulocyte/macrophage colony-stimulating factor within 1 week prior to the first study drug treatment, or use of pegylated G-CSF within 2 weeks prior to the first study drug treatment. Receiving blood transfusion treatment within 2 weeks prior to the first study drug treatment. Use of erythropoietin (EPO) or IL-11 within 1 week prior to the first study drug treatment.
- •Subjects who have not yet recovered from the toxicity of prior anticancer treatments to CTCAE grade ≤ 1 or a stable condition, except for AEs that are not considered to pose a safety risk (e.g., hair loss).
- •A history of intracranial arteriovenous malformation, cerebral aneurysm, or stroke (including transient ischemic attack within 1 month prior to screening, but excluding old cerebral infarction and asymptomatic cerebral infarction).
- •Presence of any of the following hematologic risk factors:
- •Known coagulation defects leading to an increased risk of bleeding; Diffuse alveolar hemorrhage caused by vasculitis; Persistent major bleeding; Trauma resulting in an increased risk of life-threatening bleeding; A history of severe extracranial injury or intracranial surgery within 8 weeks prior to the start of the trial.
研究组 & 干预措施
XNW34017
Experimental
干预措施: XNW34017 (Drug)
结局指标
主要结局
The incidence and severity of AEs and SAEs
时间窗: 24 months
The incidence and severity of AEs and SAEs
ORR
时间窗: 24 months
ORR assessed by investigator
次要结局
- PFS(24 months)
- DCR(24 months)
- Plasma concentrations of XNW34017(8 months)
- DOR(24 months)
- OS(24 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid TumorsNCT07310134Nanjing Zenshine Pharmaceuticals80
招募中
1 期
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor PatientsNCT07260305Kangabio AUSTRALIA LTD PTY57
招募中
1 期
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsNCT07261631Novartis Pharmaceuticals180
招募中
2 期
A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid TumorsNCT07321574Shanghai AB PharmaTech Ltd.110
招募中
不适用
TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant TumorsNCT07266298Neowise Biotechnology24